1-3 of 3
Edward E. Kadel
Close
Sort by
Journal Articles

High Expression of Programmed Death-Ligand 1 (PD-L1) Correlates with Macrophage Gene Expression and Is Associated with Prolonged Progression-Free Survival (PFS) in Patients (pts) with First-Line (1L) Diffuse Large B-Cell Lymphoma (DLBCL)

Ronald McCord, Christopher Bolen, Hartmut Koeppen, Edward E. Kadel, III, Günter Fingerle-Rowson, Mikkel Z. Oestergaard, Jeffrey M. Venstrom
Journal: Blood
Blood (2017) 130 (Supplement 1): 195.
https://doi.org/10.1182/blood.V130.Suppl_1.195.195
Published: 2017
Journal Articles

Distinct Patterns of PD-L1 and PD-L2 Expression By Tumor and Non-Tumor Cells in Patients with MM, MDS and AML

Monique Dail, Long Yang, Cherie Green, Connie Ma, Alberto Robert, Edward E. Kadel, Harmut Koeppen, Joanne Adamkewicz, John Byon, Joseph Woodard, Scott J Rodig, Jeffrey M Venstrom
Journal: Blood
Blood (2016) 128 (22): 1340.
https://doi.org/10.1182/blood.V128.22.1340.1340
Published: 2016
Journal Articles

The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells

Mohammad Luqman, Sha Klabunde, Karen Lin, Georgios V. Georgakis, Anu Cherukuri, Jocelyn Holash, Cheryl Goldbeck, Xiaomei Xu, Edward E. Kadel, III, Sang Hoon Lee, Sharon Lea Aukerman, Bahija Jallal, Natasha Aziz, Wen-Kai Weng, William Wierda, Susan O'Brien, Anas Younes
Journal: Blood
Blood (2008) 112 (3): 711–720.
https://doi.org/10.1182/blood-2007-04-084756
Published: 2008